Logo Logo Logo Logo Logo Logo
  • About us
    • About us
    • Our team
    • Join us
    • Contact us
    • Corporate social responsibility
    • Code of conduct
    • Amryt compliance
    • Aegerion Consent Decree
  • Patients and carers
    • Patients and carers
    • Homozygous familial hypercholesterolaemia
    • Lipodystrophy
    • Epidermolysis bullosa
    • Acromegaly
    • Advocacy
  • Healthcare professionals
    • Healthcare professionals
    • Our science
    • Trials and registries
    • Expanded access programme
    • Medical information enquiries
    • Grants and donations
    • Research study requests
  • Product portfolio
    • Product portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Pipeline
  • Newsroom
  • Investors
    • The Company
    • News
    • Reports and presentations
    • Stock information
    • Events
    • Corporate governance
    • AIM Delisting
    • Contingent Value Rights (CVR) FAQ
    • Analysts
    • Contacts and advisors
  • Business development
  • About us
    • About us
    • Our team
    • Join us
    • Contact us
    • Corporate social responsibility
    • Code of conduct
    • Amryt compliance
    • Aegerion Consent Decree
  • Patients and carers
    • Patients and carers
    • Homozygous familial hypercholesterolaemia
    • Lipodystrophy
    • Epidermolysis bullosa
    • Acromegaly
    • Advocacy
  • Healthcare professionals
    • Healthcare professionals
    • Our science
    • Trials and registries
    • Expanded access programme
    • Medical information enquiries
    • Grants and donations
    • Research study requests
  • Product portfolio
    • Product portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Pipeline
  • Newsroom
  • Investors
    • The Company
    • News
    • Reports and presentations
    • Stock information
    • Events
    • Corporate governance
    • AIM Delisting
    • Contingent Value Rights (CVR) FAQ
    • Analysts
    • Contacts and advisors
  • Business development

Newsroom

  • News
  • SEC Filings
  • Media Backgrounders

Notices

01 June 2022 Notice of General Meeting PDF
01 June 2022 General Meeting Form of Proxy PDF
07 February 2022 Notice of General Meeting PDF
07 February 2022 General Meeting Form of Proxy PDF
Homozygous familial hypercholesterolaemia (HoFH) PDF
Juxtapid® / Lojuxta®▼ PDF
Lipodystrophy PDF
Oleogel-S10 PDF
Epidermolysis Bullosa PDF
Myalept® / Myalepta®▼ (metreleptin) PDF
Acromegaly PDF
Amryt Pharma

We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need.

Privacy policy | Terms and Conditions | Modern Slavery Statement
Cookie policy | Fraud warning
Accessibility | Sitemap

Copyright © 2022 Amryt Pharma plc